HLA-C and neoplasm: In parallel, TCR-mimetic bispecific antibodies (TCR-mimic bsAbs) have been generated to bind intracellularly derived peptide–MHC complexes with antibody-like specificity, extending the reach of bsAb therapies to non-surface tumor antigens such as mutated p53 or KRAS [77, 78].